Melanoma is one of the most aggressive skin cancers, known for its high potential to spread to other parts of the body (metastasize) and its historical resistance to conventional treatments like chemotherapy. Just 15 years ago, advanced melanoma had a median survival of only 6 to 9 months.
This review explores how the treatment landscape has been completely transformed by two major breakthroughs: targeted therapies against BRAF mutations and immunotherapies (particularly immune checkpoint inhibitors). These advances have significantly extended survival and improved quality of life for patients with advanced melanoma.
The paper asks a provocative question in its title: 'Is a cure now in sight?' The answer, based on the evidence reviewed, is cautiously optimistic. Some patients are now living 10+ years after diagnosis with advanced melanoma, which was virtually unheard of before these treatments existed.
About 40-50% of melanomas have a mutation in a gene called BRAF (most commonly BRAF V600E). This mutation causes a protein to be permanently 'switched on,' driving uncontrolled cell growth. Drugs called BRAF inhibitors (like dabrafenib and vemurafenib) can block this overactive protein.
However, melanoma is smart. Tumors treated with BRAF inhibitors alone usually find workaround pathways and become resistant within months. The solution was to combine BRAF inhibitors with MEK inhibitors (like trametinib), which block a related protein in the same signaling pathway. This double blockade makes it much harder for the cancer to develop resistance.
The combination of dabrafenib plus trametinib has shown 5-year overall survival rates of around 34% in patients with advanced BRAF-mutated melanoma, a dramatic improvement over the pre-targeted therapy era.
The biggest revolution in melanoma treatment has been immune checkpoint inhibitors. These drugs block proteins that cancer cells use to hide from the immune system. The two key targets are CTLA-4 (blocked by ipilimumab/Yervoy) and PD-1 (blocked by nivolumab/Opdivo and pembrolizumab/Keytruda).
The combination of nivolumab plus ipilimumab has shown 6.5-year overall survival rates of around 49% in advanced melanoma, meaning nearly half of patients were still alive after more than 6 years. Some patients who responded to treatment have remained cancer-free for over a decade, suggesting that immunotherapy can produce durable, potentially curative responses.
The review discusses how these treatments are now being used in earlier-stage disease (adjuvant and neoadjuvant settings) to prevent recurrence after surgery, with impressive results. The CheckMate and KEYNOTE trial series have been pivotal in establishing these approaches.
The review covers several exciting newer approaches. Tumor-infiltrating lymphocyte (TIL) therapy involves extracting immune cells directly from a patient's tumor, growing billions of copies in the lab, and infusing them back into the patient. The FDA-approved TIL therapy lifileucel (Amtagvi) showed a 31.4% overall response rate in previously treated advanced melanoma.
Oncolytic viruses are engineered viruses that selectively infect and kill cancer cells while leaving healthy cells unharmed. Talimogene laherparepvec (T-VEC) was the first FDA-approved oncolytic virus and is injected directly into melanoma tumors, where it both kills cancer cells and stimulates an immune response.
Personalized cancer vaccines, designed to target unique mutations (neoantigens) found only in an individual patient's tumor, are also showing promise in clinical trials. These vaccines essentially train the immune system to recognize and attack cancer cells carrying those specific mutations.
Despite these remarkable advances, the review notes several persistent challenges. Drug resistance remains the biggest obstacle. While many patients respond initially, some eventually develop resistance, and researchers are still working to understand and overcome the mechanisms behind it.
Immune-related side effects are another concern. Because checkpoint inhibitors work by activating the immune system, they can sometimes cause the immune system to attack healthy organs (autoimmune side effects). These can affect the thyroid, liver, lungs, intestines, and other organs, and in rare cases can be life-threatening.
Finally, access to these cutting-edge treatments is uneven globally. The high cost of immunotherapy and targeted therapy, combined with limited availability in lower-income countries, means many melanoma patients worldwide still do not have access to potentially life-saving treatments.